SUPPLEMENTARY FINANCIAL DATA (UNAUDITED)

12 Months Ended

Dec. 31, 2023

SUPPLEMENTARY FINANCIAL DATA (UNAUDITED)

SUPPLEMENTARY FINANCIAL DATA (UNAUDITED)

SUPPLEMENTARY FINANCIAL DATA

(UNAUDITED)

(In thousands, except per share data)

The following table presents certain unaudited consolidated quarterly financial information for the eight quarters in the periods ended December 31, 2023 and 2022. This information has been prepared on the same basis as the audited consolidated financial statements and includes all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the unaudited quarterly results of operations set forth herein. For all periods prior to the quarter ended September 30, 2022, the information below has been retroactively adjusted for discontinued operations presentation.

	For the Quarter Ended
	March 31,		June 30,		September 30,		December 31,
2023
Total revenue	$	10,417	$	13,749	$	15,693	$	17,565
Costs and expenses		35,329		29,872		24,453		23,805
Loss from operations		(24,912)		(16,123)		(8,760)		(6,240)
Net loss from continuing operations		(22,088)		(15,645)		(8,950)		(8,510)
Net income from discontinued operations		—		—		—		—
Net income (loss)		(22,088)		(15,645)		(8,950)		(8,510)
Net loss from continuing operations - basic and diluted per share		(0.35)		(0.28)		(0.17)		(0.17)
Net income from discontinued operations - basis and diluted per share		—		—		—		-
Net income (loss) - basis and diluted per share	$	(0.35)	$	(0.28)	$	(0.17)	$	(0.17)
2022
Total revenue	$	13,196	$	11,050	$	12,451	$	14,649
Costs and expenses		51,698		37,929		21,595		32,081
Loss from operations		(38,502)		(26,879)		(9,144)		(17,432)
Net loss from continuing operations		(41,538)		(26,570)		(10,460)		(14,256)
Net income from discontinued operations		15,592		18,379		927,091		3,894
Net income (loss)		(25,946)		(8,191)		916,631		(10,362)
Net loss from continuing operations - basic and diluted per share		(0.55)		(0.35)		(0.21)		(0.21)
Net income from discontinued operations - basis and diluted per share		0.21		0.24		12.35		0.06
Net income (loss) - basis and diluted per share	$	(0.34)		(0.11)		12.14		(0.15)
Share of Total YUPELRI Net Sales (1)
	For the Quarter Ended
	March 31,		June 30,		September 30,		December 31,
2023	$	16,434	$	19,263	$	20,414	$	21,225
2022	$	15,283	$	17,177	$	18,698	$	19,495

(1) The Company co-promotes YUPELRI in the US under a profit and loss sharing arrangement with Viatris (65% to Viatris; 35% to Theravance Biopharma). The amounts represent the Company’s implied 35% share of the total net sales of YUPELRI that were recognized within Viatris’ financial statements for the periods presented.